

approach fix (FAF), and to contain the departure procedure starting at JODRO—given that arrivals are visual flight rules (VFR) after the FAF, and departures are VFR until reaching JODRO.

In addition, the Chenega, AK, Class E airspace extending upward from 700 feet above the surface of the earth is extended to the north of the airport to contain arriving IFR operations below 1,500 feet above the surface until reaching the FAF.

Finally, the FAA is modifying the airport's associated legal description to update the city name within the text header from "Chenega Bay, AK" to "Chenega, AK."

Regulatory Notices and Analyses

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore: (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that only affects air traffic procedures and air navigation, it is certified that this rule, when promulgated, does not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

Environmental Review

The FAA has determined that this action qualifies for categorical exclusion under the National Environmental Policy Act in accordance with FAA Order 1050.1F, "Environmental Impacts: Policies and Procedures," paragraph 5–6.5.a. This airspace action is not expected to cause any potentially significant environmental impacts, and no extraordinary circumstances exist that warrant preparation of an environmental assessment.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

■ 1. The authority citation for 14 CFR part 71 continues to read as follows:

Authority: 49 U.S.C. 106(f), 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

■ 2. The incorporation by reference in 14 CFR part 71.1 of FAA Order JO 7400.11], Airspace Designations and Reporting Points, dated July 31, 2024, and effective September 15, 2024, is amended as follows:

Paragraph 6005 Class E Airspace Areas Extending Upward From 700 Feet or More Above the Surface of the Earth.

* * * * *

AAL AK E5 Chenega, AK [Amended]

Chenega Bay Airport, AK
(Lat. 60°04'43" N, long. 147°59'41" W)

That airspace extending upward from 700 feet above the surface within an area bounded by a line beginning at lat. 60°11'28" N, long. 148°4'30" W; to lat. 60°18'43" N, long. 147°59'37" W; to lat. 60°18'23" N, long. 147°55'19" W; to lat. 60°14'30" N, long. 147°56'37" W; to lat. 60°5'57" N, long. 147°37'29" W; to lat. 60°3'26" N, long. 147°42'48" W; thence to the point of beginning.

* * * * *

Issued in Des Moines, Washington, on November 25, 2024.

B.G. Chew,
*Group Manager, Operations Support Group,
Western Service Center.*

[FR Doc. 2024–28135 Filed 11–29–24; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

15 CFR Part 922

[Docket No. 240829–0230]

RIN 0648–BL31

Chumash Heritage National Marine Sanctuary

AGENCY: Office of National Marine Sanctuaries, National Ocean Service, National Oceanic and Atmospheric Administration, Department of Commerce.

ACTION: Notification of effective date of final rule.

SUMMARY: The National Oceanic and Atmospheric Administration (NOAA) is

providing notice that the final rule published on October 16, 2024, to designate Chumash Heritage National Marine Sanctuary (CHNMS), is effective on November 30, 2024.

DATES: The final rule to designate CHNMS, which was published in the **Federal Register** (89 FR 83554) on October 16, 2024, is effective November 30, 2024.

FOR FURTHER INFORMATION CONTACT:

Laura Ingulsrud, West Coast Regional Policy Analyst, 99 Pacific Street, Suite 100F, Monterey, CA 93940, 831–647–6450, laura.ingulsrud@noaa.gov.

SUPPLEMENTARY INFORMATION: Pursuant to Section 304(b) of the National Marine Sanctuaries Act (NMSA) (16 U.S.C. 1434(b)), NOAA published in the **Federal Register** notification of the designation of CHNMS and final regulations to implement the designation on October 16, 2024 (89 FR 83554). As required by the NMSA, the designation and regulations would become effective following the close of a review period of 45 days of continuous session of Congress beginning on the date of publication (16 U.S.C. 1434(b)(1)). The regulations are effective as of November 30, 2024.

List of Subjects in 15 CFR Part 922

Administrative practice and procedure, Coastal zone, Cultural resources, Historic preservation, Marine protected areas, Marine resources, National marine sanctuaries, Recreation and recreation areas, Reporting and recordkeeping requirements, Shipwrecks.

John Armor,

*Director, Office of National Marine Sanctuaries, National Ocean Service,
National Oceanic and Atmospheric Administration.*

[FR Doc. 2024–27387 Filed 11–29–24; 8:45 am]

BILLING CODE 3510–NK–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, 524, and 558

[Docket No. FDA–2024–N–0002]

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during July, August, and September 2024. The animal drug regulations are also being amended to improve their accuracy and readability.

DATES: This rule is effective December 2, 2024.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, George.Haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Approvals

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during July, August, and September 2024, as listed

in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval under the Freedom of Information Act. These documents, along with marketing exclusivity and patent information, may be obtained at Animal Drugs @FDA: <https://animaldrugsatfda.fda.gov/adafda/views/#/search>.

TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAs AND ANADAs APPROVED DURING JULY, AUGUST, AND SEPTEMBER 2024 REQUIRING EVIDENCE OF SAFETY AND/OR EFFECTIVENESS

Date of approval	File No.	Sponsor (drug labeler code ¹)	Product name	Effect of the action	21 CFR section
July 2, 2024	200-788	Bimeda Animal Health Ltd. (061133)	MOXISOLV Injection (moxidectin)	Original approval as a generic copy of NADA 141-220.	522.1450
July 8, 2024	200-771	Norbrook Laboratories, Ltd. (055529)	FELANORM (methimazole) Oral Solution.	Original approval as a generic copy of NADA 141-292.	520.1372
August 15, 2024	200-770	Pharmgate Inc. (069254)	DERACIN (chlortetracycline) and MGA (melengestrol acetate) Type C medicated feeds.	Original approval as a generic copy of NADA 141-530.	558.128
August 26, 2024	200-783	Huvepharma EOOD (016592)	COXIDIN 90 (monensin) Type C medicated feeds.	Original approval as a generic copy of NADA 038-878 and NADA 130-736.	558.355
September 5, 2024	200-795	Felix Pharmaceuticals Pvt. Ltd. (086101).	CARPROFEN Soft Chewable Tablets (carprofen).	Original approval as a generic copy of NADA 141-111.	520.304
September 5, 2024	200-773	Cronus Pharma Specialties India Private Ltd. (069043).	TULAJECT 100 (tulathromycin injection) Injectable Solution.	Original approval as a generic copy of NADA 141-224.	522.2630
September 10, 2024 ...	200-774	Do	TULAJECT 25 (tulathromycin injection) Injectable Solution.	Original approval as a generic copy of NADA 141-349.	Do.
September 19, 2024 ...	141-585	Elanco US Inc. (058198)	ZENRELIA (ilunocitinib tablet)	Original approval for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.	520.1136
September 23, 2024 ...	200-776	Pharmgate Inc. (069254)	DERACIN (chlortetracycline), BOVATEC (lasalocid), and MGA (melengestrol acetate) Type C medicated feeds.	Original approval as a generic copy of NADA 141-531.	558.128

¹ See 21 CFR 510.600(c) for sponsor addresses.

II. Withdrawals of Approval

Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767-1861

(drug labeler code 054925) requested that FDA withdraw approval of the two NADAs listed in table 2 because the products are no longer manufactured or

marketed. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these actions.

TABLE 2—APPLICATIONS FOR WHICH APPROVAL WAS VOLUNTARILY WITHDRAWN DURING JULY, AUGUST, AND SEPTEMBER 2024

Date of withdrawal of approval	File No.	Product name	21 CFR section
August 8, 2024	130-872	Nitrofurazone Anesthetic Dressing (nitrofurazone and butacaine sulfate)	524.1580c
Do	140-881	Nitrofurazone Soluble Dressing (nitrofurazone)	524.1580a

III. Change of Sponsor

Cephazone Pharma, LLC, 250 East Bonita Ave., Pomona, CA 91767 has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-420 for Ceftiofur Sodium Sterile Powder to Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211. As provided in the regulatory

text, the animal drug regulations are amended to reflect this action.

IV. Technical Amendments

FDA is making the following amendments to improve the accuracy and readability of the animal drug regulations:

- 21 CFR 510.600(c) is amended to remove Cephazone Pharma, LLC and Provetica LLC from the lists of sponsors

of approved applications as these firms are no longer the sponsor of an approved application.

- 21 CFR 520.522 is amended to reflect a 2023 change of sponsorship for cyclosporine oral solution.
- 21 CFR 520.2090 is amended to revise the description of a tablet containing sarolaner, moxidectin, and pyrantel.

• 21 CFR 522.2470 is being amended to reflect previous approval of additional indications for use of tiletamine and zolazepam.

V. Legal Authority

This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(i)). Although deemed a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability” and is not subject to the congressional review requirements in 5 U.S.C. 801–808. Likewise, this is not a rule subject to Executive Order 12866.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, and 524

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 520, 522, 524, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

■ 2. In § 510.600, in the table in paragraph (c)(1), remove the entries for “Cephazone Pharma, LLC” and “Provetica LLC”; and in the table in paragraph (c)(2), remove the entries for “068330” and “086097”.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.304 [Amended]

■ 4. In § 520.304, in paragraph (b)(2), add in numerical order the text “086101”.

§ 520.522 [Amended]

■ 5. In § 520.522 in paragraph (b)(4), remove the text “086097” and add in its place the text “013744”.

■ 6. Add § 520.1136 to read as follows:

§ 520.1136 Ilunocitinib.

(a) *Specifications.* Each tablet contains 4.8, 6.4, 8.5, and 15 milligrams (mg) ilunocitinib.

(b) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.

(c) *Conditions of use—(1) Amount.* Administer orally 0.27 to 0.36 mg ilunocitinib/lb (0.6 to 0.8 mg ilunocitinib/kg) body weight, once daily, with or without food.

(2) *Indications for use.* For the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1372 [Redesignated as § 520.1375]

■ 7. Redesignate § 520.1372 as § 520.1375 and revise the section heading to read as follows:

§ 520.1375 Methimazole tablets.

* * * * *

■ 8. Add § 520.1376 to read as follows:

§ 520.1376 Methimazole solution.

(a) *Specifications.* Each milliliter of solution contains 5 milligrams (mg) methimazole.

(b) *Sponsor.* See No. 055529 in § 510.600(c) of this chapter.

(c) *Conditions of use in cats—(1) Amount.* Administer a starting dose of 2.5 mg every 12 hours. Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 (TT4) levels and clinical response. Dose adjustments should be made in 2.5 mg increments with a maximum dosage of 20 mg per day divided, not to exceed 10 mg as a single dose.

(2) *Indications for use.* For the treatment of hyperthyroidism.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

■ 9. In § 520.2090, revise paragraph (a)(1) to read as follows:

§ 520.2090 Sarolaner, moxidectin, and pyrantel.

(a) * * *

(1) 3.0 milligrams (mg) sarolaner, 0.06 mg moxidectin, and 12.5 mg pyrantel (as pamoate salt);

* * * * *

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 10. The authority citation for part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 11. In § 522.313c, revise paragraph (b) to read as follows:

§ 522.313c Ceftiofur sodium.

* * * * *

(b) *Sponsors.* See Nos. 017033 and 054771 in § 510.600(c) of this chapter.

* * * * *

■ 12. In § 522.1450, revise paragraph (b) to read as follows:

§ 522.1450 Moxidectin solution.

* * * * *

(b) *Sponsors.* See Nos. 055529, 058198, and 061133 in § 510.600(c) of this chapter.

* * * * *

■ 13. In § 522.2470, revise the section heading and paragraph (b) to read as follows:

§ 522.2470 Tiletamine and zolazepam.

* * * * *

(b) *Sponsors.* See Nos. 017033, 051311, and 054771 in § 510.600(c) of this chapter.

* * * * *

§ 522.2630 [Amended]

■ 14. In § 522.2630, in paragraphs (b)(1) and (2), add in numerical order the text “069043”.

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

■ 15. The authority citation for part 524 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 524.1580a [Amended]

■ 16. Amend § 524.1580a in paragraph (b)(1) by removing the text “054925”.

§ 524.1580c [Removed]

■ 17. Remove § 524.1580c.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 18. The authority citation for part 558 continues to read as follows:

Authority: 21 U.S.C. 354, 360b, 360ccc, 360ccc–1, 371.

■ 19. In § 558.128, revise paragraphs (e)(4)(ii), (vi), (viii), (xxviii), (xxxii), (xxxiii), (xxxv), (xxxvi), (xxxix), (xli), (xlii), (li), (lii), (liv), (lvi), (lvii), (lix), and (lx) to read as follows:

§ 558.128 Chlortetracycline.

* * * * *

(e) * * *

(4) * * *

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
(ii) 5.83 to 14 g/ton to provide 70 mg/head/day.	Melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg melengestrol acetate per head per day.	Growing beef heifers fed in confinement for slaughter (over 400 lb): For reduction of the incidence of liver abscesses, increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed or mixed at feeding with the Type C medicated feed containing 5.83 to 14 g/ton chlortetracycline. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(vi) 33.33 to 50 g/ton to provide 0.5 mg/lb of body weight per day.	Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg melengestrol acetate per head per day.	Replacement beef heifers over 700 lb: For control of active infection of anaplasmosis caused by <i>Anaplasma marginale</i> susceptible to chlortetracycline and for suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed or mixed at feeding with the Type C medicated feed containing 33.33 to 50 g/ton chlortetracycline. Feeding a Type C top-dress medicated feed containing melengestrol acetate shall not exceed 24 days. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(viii) 25 to 1,100 g/ton to provide 0.5 mg/lb of body weight daily.	Lasalocid, 30 to 600; melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement beef heifers on pasture over 700 pounds: For control of active infection of anaplasmosis caused by <i>Anaplasma marginale</i> susceptible to chlortetracycline, increased rate of weight gain, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 1,100 g/ton of chlortetracycline and 30 to 600 g/ton lasalocid to provide 0.5 mg chlortetracycline per lb body weight per day and not less than 60 mg or more than 300 mg lasalocid per head per day in at least 1 pound of feed. Do not exceed 24 days of feeding. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(xxviii) 500 to 4,000 g/ton to provide 10 mg/lb of body weight daily.	Lasalocid, 30 to 600; Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement dairy heifers on pasture less than 20 months of age and replacement beef heifers on pasture: For treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, increased rate of weight gain, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 500 to 4,000 g/ton of chlortetracycline and 30 to 600 g/ton lasalocid to provide 10 mg chlortetracycline per lb body weight per day and not less than 60 mg or more than 300 mg lasalocid per head per day in at least 1 pound of feed for not more than 5 days. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone for a total time not exceeding 24 days of feeding. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254, lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(xxx) 500 to 4,000 g/ton to provide 10 mg/lb of body weight daily.	Melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg melengestrol acetate per head per day.	Growing beef heifers fed in confinement for slaughter: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 500 to 4,000 g/ton chlortetracycline for not more than 5 days. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
(xxxii) 500 to 4,000 g/ton to provide 10 mg/lb of body weight daily.	Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg melengestrol acetate per head per day.	Replacement dairy heifers less than 20 months of age and replacement beef heifers: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, and for suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed or mixed at feeding with a Type C medicated feed containing 500 to 4,000 g/ton chlortetracycline for not more than 5 days. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone for a total time not exceeding 24 days. Use in dairy heifers less than 20 months of age may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(xxxv) 4,000 to 20,000 g/ton to provide 10 mg/lb of body weight per day.	Melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg melengestrol acetate per head per day.	Growing beef heifers fed in confinement for slaughter: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, and for increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	Top dress 0.5 to 2 pounds of this medicated feed containing both drugs onto or mix at feeding with a non-medicated feed for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(xxxvi) 4,000 to 20,000 g/ton to provide 10 mg/lb of body weight per day.	Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg melengestrol acetate per head per day.	Replacement dairy heifers less than 20 months of age and replacement beef heifers: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, and for suppression of estrus (heat).	Top dress 0.5 to 2 pounds of this medicated feed containing both drugs onto or mix at feeding with a non-medicated feed for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone for a total time not exceeding 24 days. Use in dairy heifers less than 20 months of age may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(xxxix) 50 to 350 g/ton to provide 350 mg/head/day.	Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg melengestrol acetate per head per day.	Replacement beef heifers under 700 lb: For control of active infection of anaplasmosis caused by <i>Anaplasma marginale</i> susceptible to chlortetracycline and for suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed or mixed at feeding with the Type C medicated feed containing 50 to 350 g/ton chlortetracycline for up to 24 days of feeding. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(xli) 20 to 350 g/ton to provide 350 mg/head/day.	Melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg melengestrol acetate per head per day.	Growing beef heifers fed in confinement for slaughter: For control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline, increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with the Type C medicated feed containing 20 to 350 g/ton chlortetracycline. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
(xlii) 20 to 350 g/ton to provide 350 mg/head/day.	Melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg melengestrol acetate per head per day.	Replacement dairy heifers less than 20 months of age and replacement beef heifers: For control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline and suppression of estrus (heat).	Melengestrol acetate Type C top-dress medicated feed must be top dressed or mixed at feeding with the Type C medicated feed containing 20 to 350 g/ton chlortetracycline. Feeding a Type C top-dress medicated feed containing melengestrol acetate shall not exceed 24 days of feeding. Use in dairy heifers less than 20 months of age may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Chlortetracycline as provided by Nos. 054771 or 069254; melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(l) 25 to 700 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 600; melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement beef heifers on pasture: For control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline, increased rate of weight gain, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 700 g/ton of chlortetracycline and 30 to 600 g/ton lasalocid to provide 350 mg chlortetracycline per head daily and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 pound of feed. Do not exceed 24 days of feeding. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(lii) 25 to 700 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 600; melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement beef heifers on pasture under 700 pounds: For control of active infection of anaplasmosis caused by <i>Anaplasma marginale</i> susceptible to chlortetracycline, increased rate of weight gain, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 700 g/ton of chlortetracycline and 30 to 600 g/ton lasalocid to provide 350 mg chlortetracycline per head daily and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 pound of feed. Do not exceed 24 days of feeding. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(liv) 25 to 2,800 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg/head/day melengestrol acetate.	Growing beef heifers fed in confinement for slaughter under 700 pounds: For control of active infection of anaplasmosis caused by <i>Anaplasma marginale</i> susceptible to chlortetracycline, control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E. zuernii</i> , increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 2,800 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 350 mg chlortetracycline per head per day and 1 mg lasalocid per 2.2 lb. of body weight daily with a maximum of 360 mg lasalocid per head per day. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*
(lvi) 25 to 2,800 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg/head/day melengestrol acetate.	Growing beef heifers fed in confinement for slaughter up to 800 pounds: For control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline, control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E. zuernii</i> , increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 2,800 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 350 mg chlortetracycline per head daily and 1 mg lasalocid per 2.2 lb. of body weight daily with a maximum of 360 mg lasalocid per head per day. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
*	*	*	*	*

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
(lvii) 25 to 2,800 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement beef heifers up to 800 pounds: For control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline, control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E. zuernii</i> , and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 2,800 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 350 mg chlortetracycline per head daily and 1 mg lasalocid per 2.2 lb. of body weight daily with a maximum of 360 mg lasalocid per head per day. Do not exceed 24 days of feeding. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(lix) 500 to 4,000 g/ton to provide 10 mg/lb of body weight daily.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg/head/day melengestrol acetate.	Growing beef heifers fed in confinement for slaughter up to 800 pounds: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E. zuernii</i> , increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 500 to 4,000 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 10 mg chlortetracycline per lb of body weight per day and 1 mg lasalocid per 2.2 lb of body weight per day with a maximum of 360 mg lasalocid per head per day for not more than 5 days of feeding. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254
(lx) 500 to 4,000 g/ton to provide 10 mg/lb of body weight daily.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.5 to 2 g/ton to provide 0.5 mg/head/day melengestrol acetate.	Replacement dairy heifers up to 800 pounds and less than 20 months of age and replacement beef heifers up to 800 pounds: For the treatment of bacterial enteritis caused by <i>Escherichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline, control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E. zuernii</i> , and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 500 to 4,000 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 10 mg chlortetracycline per lb of body weight per day and 1 mg lasalocid per 2.2 lb of body weight per day with a maximum of 360 mg lasalocid per head per day for not more than 5 days. After completing feeding of this combination, continue feeding a Type C top-dress medicated feed containing melengestrol acetate alone. See § 558.311(d) of this chapter. Chlortetracycline as provided by Nos. 054771 or 069254; lasalocid and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771 069254

- * * * * *
- 20. In § 558.355:
- a. Revise paragraphs (b)(1) and (2);
- b. Revise the headings for paragraphs (d)(9)(i) and (ii) and (d)(10)(i) and (ii);
- c. Redesignate paragraph (f) as paragraph (e);
- d. Revise newly redesignated paragraphs (e)(1)(i) and (ii), (e)(2)(i), and (e)(5);
- e. Remove newly redesignated paragraph (e)(6); and
- f. Redesignate newly redesignated paragraph (e)(7) as paragraph (e)(6).
The revisions read as follows:

§ 558.355 Monensin.
 * * * * *
 (b) * * *
 (1) No. 058198 for use as in paragraph (e) of this section.
 (2) No. 016592 for use of a Type A medicated article containing 90.7 grams monensin, USP, per pound as in paragraphs (e)(1)(i), (e)(1)(ii), (e)(2)(i), (e)(3), (e)(4)(v), and (e)(5) of this section.
 * * * * *
 (d) * * *
 (9) * * *
 (i) Cattle (as described in paragraphs (e)(3)(i) through (iii), (vi), and (vii); and

(e)(4)(i) through (vi) of this section).
 * * *
 (ii) Dairy cows (as described in paragraphs (e)(3)(iv) and (v) of this section). * * *
 (10) * * *
 (i) Cattle (as described in paragraphs (e)(3)(i) through (iii), (vi), and (vii); and (e)(4)(i) through (vi) of this section). * * *
 (ii) Dairy cows (as described in paragraphs (e)(3)(iv) and (v) of this section). * * *
 * * * * *
 (e) * * *
 (1) * * *

Monensin in grams/ton	Combination in grams/ton	Indications for use	Limitations	Sponsor
(i) 90 to 110		Broiler chickens: As an aid in the prevention of coccidiosis caused by <i>E. necatrix</i> , <i>E. tenella</i> , <i>E. acervulina</i> , <i>E. brunetti</i> , <i>E. mivati</i> , and <i>E. maxima</i> .	Feed continuously as the sole ration. Not for broiler breeder replacement chickens. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. In the absence of coccidiosis in broiler chickens the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.	016592 058198
(ii) 90 to 110		Laying hen replacement chickens and layer breeder replacement chickens: As an aid in the prevention of coccidiosis caused by <i>E. necatrix</i> , <i>E. tenella</i> , <i>E. acervulina</i> , <i>E. brunetti</i> , <i>E. mivati</i> , and <i>E. maxima</i> .	Feed continuously as the sole ration. Not for broiler breeder replacement chickens. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. In the absence of coccidiosis in broiler chickens the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.	016592 058198
	*	*	*	*

(2) * * *

Monensin in grams/ton	Combination in grams/ton	Indications for use	Limitations	Sponsor
(i) 54 to 90		Growing turkeys: For the prevention of coccidiosis caused by <i>E. adenoeides</i> , <i>E. meleagrimitis</i> , and <i>E.gallopavonis</i> .	For growing turkeys only. Feed continuously as sole ration. Some strains of turkey coccidia may be monensin tolerant or resistant. Not for broiler breeder replacement chickens. Do not feed to laying hens. Do not feed to chickens over 16 weeks of age. Monensin may interfere with development of immunity to turkey coccidiosis. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.	016592 058198
	*	*	*	*

(5) *Minor species*—

Monensin in grams/ton	Indications for use	Limitations	Sponsor
(i) 73	Growing bobwhite quail: For the prevention of coccidiosis caused by <i>Eimeria dispersa</i> and <i>E. lettyae</i> .	Feed continuously as sole ration. Not for broiler breeder replacement chickens. Do not feed to laying hens. Do not feed to chickens over 16 weeks of age. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.	016592 058198
(ii) 20	Goats maintained in confinement: For the prevention of coccidiosis caused by <i>Eimeria crandallis</i> , <i>E. christenseni</i> , and <i>E. ninakohlyakimovae</i> .	Feed continuously. Do not feed to lactating goats. See paragraph (d)(11) of this section for provisions for monensin liquid Type C goat feeds.	016592 058198
	*	*	*

* * * * *

Dated: November 20, 2024.

P. Ritu Nalubola,

Associate Commissioner for Policy.

[FR Doc. 2024-28061 Filed 11-29-24; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[TD 10014]

RIN 1545-BL21

Recourse Partnership Liabilities and Related Party Rules

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Final rule.

SUMMARY: This document contains final regulations relating to recourse liabilities of a partnership and special rules for related persons. These

regulations affect partnerships and their partners.

DATES:

Effective date: These regulations are effective on December 2, 2024.

Applicability dates: For dates of applicability, see §§ 1.704-2(l)(1)(vi), 1.752-2(l)(4), and 1.752-5(a).

FOR FURTHER INFORMATION CONTACT:

Concerning these final regulations, contact Caroline Hay of the Office of Associate Chief Counsel (Passthroughs and Special Industries), (202) 317-6850 (not a toll-free number).

SUPPLEMENTARY INFORMATION:

Authority

This document amends the Income Tax Regulations (26 CFR part 1) under